Copyright © 2012 Maki Urushihara et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. L. G. Navar, L. M. Harrison-Bernard, J. D. Imig, C. T. Wang, L. Cervenka, and K. D. Mitchell, “Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade,” Journal of the American Society of Nephrology, vol. 10, supplement 12, pp. S266–S272, 1999. View at Scopus
2. H. Kobori, M. Nangaku, L. G. Navar, and A. Nishiyama, “The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease,” Pharmacological Reviews, vol. 59, no. 3, pp. 251–287, 2007. View at Publisher · View at Google Scholar · View at Scopus
3. R. M. Carey and H. M. Siragy, “The intrarenal renin-angiotensin system and diabetic nephropathy,” Trends in Endocrinology and Metabolism, vol. 14, no. 6, pp. 274–281, 2003. View at Publisher · View at Google Scholar · View at Scopus
4. R. A. S. Santos, A. C. Simoes e Silva, C. Maric et al., “Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8258–8263, 2003. View at Publisher · View at Google Scholar · View at Scopus
5. L. G. Navar, M. C. Prieto-Carrasquero, and H. Kobori, Chapter 1: Molecular Aspects of the Renal Renin-Angiotensin System, Taylor & Francis Medical, Oxfordshine, UK, 1st edition, 2006.
6. V. J. Dzau and R. Re, “Tissue angiotensin system in cardiovascular medicine: a paradigm shift?” Circulation, vol. 89, no. 1, pp. 493–498, 1994. View at Scopus
7. O. Baltatu, J. A. Silva Jr., D. Ganten, and M. Bader, “The brain renin-angiotensin system modulates angiotensin II-induced hypertension and cardiac hypertrophy,” Hypertension, vol. 35, no. 1, part 2, pp. 409–412, 2000. View at Scopus
8. L. J. Dell'Italia, Q. C. Meng, E. Balcells et al., “Compartmentalization of angiotensin II generation in the dog heart: evidence for independent mechanisms in intravascular and interstitial spaces,” Journal of Clinical Investigation, vol. 100, no. 2, pp. 253–258, 1997. View at Scopus
9. G. Mazzocchi, L. K. Malendowicz, A. Markowska, G. Albertin, and G. G. Nussdorfer, “Role of adrenal renin-angiotensin system in the control of aldosterone secretion in sodium-restricted rats,” American Journal of Physiology, vol. 278, no. 6, pp. E1027–E1030, 2000. View at Scopus
10. K. K. Griendling, C. A. Minieri, J. D. Ollerenshaw, and R. W. Alexander, “Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells,” Circulation Research, vol. 74, no. 6, pp. 1141–1148, 1994. View at Scopus
11. A. H. J. Danser, P. J. J. Admiraal, F. H. M. Derkx, and M. A. D. H. Schalekamp, “Angiotensin I-to-II conversion in the human renal vascular bed,” Journal of Hypertension, vol. 16, no. 12, part 2, pp. 2051–2056, 1998. View at Publisher · View at Google Scholar · View at Scopus
12. L. G. Navar, L. M. Harrison-Bernard, A. Nishiyama, and H. Kobori, “Regulation of intrarenal angiotensin II in hypertension,” Hypertension, vol. 39, no. 2, part 2, pp. 316–322, 2002. View at Publisher · View at Google Scholar · View at Scopus
13. A. R. Brasier and J. Li, “Mechanisms for inducible control of angiotensinogen gene transcription,” Hypertension, vol. 27, no. 3, part 2, pp. 465–475, 1996. View at Scopus
14. W. L. Henrich, E. A. McAllister, A. Eskue, T. Miller, and O. W. Moe, “Renin regulation in cultured proximal tubular cells,” Hypertension, vol. 27, no. 6, pp. 1337–1340, 1996. View at Scopus
15. M. Sibony, J. M. Gasc, F. Soubrier, F. Alhenc-Gelas, and P. Corvol, “Gene expression and tissue localization of the two isoforms of angiotensin I converting enzyme,” Hypertension, vol. 21, no. 6, part 1, pp. 827–835, 1993. View at Scopus
16. C. P. Vío and V. A. Jeanneret, “Local induction of angiotensin-converting enzyme in the kidney as a mechanism of progressive renal diseases,” Kidney International, Supplement, vol. 64, no. 86, pp. S57–S63, 2003. View at Scopus
17. D. E. Casarini, M. A. Boim, R. C. R. Stella, M. H. Krieger-Azzolini, J. E. Krieger, and N. Schor, “Angiotensin I-converting enzyme activity in tubular fluid along the rat nephron,” American Journal of Physiology, vol. 272, no. 3, part 2, pp. F405–F409, 1997. View at Scopus
18. D. E. Kohan, “Angiotensin II and endothelin in chronic glomerulonephritis,” Kidney International, vol. 54, no. 2, pp. 646–647, 1998. View at Publisher · View at Google Scholar · View at Scopus
19. M. Urushihara and H. Kobori, “Angiotensinogen expression is enhanced in the progression of glomerular disease,” International Journal of Clinical Medicine, vol. 2, no. 4, pp. 378–387, 2011.
20. Y. Horita, M. Tadokoro, K. Taura et al., “Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin A nephropathy,” Hypertension Research, vol. 27, no. 12, pp. 963–970, 2004. View at Publisher · View at Google Scholar · View at Scopus
21. P. Ruggenenti, A. Perna, G. Gherardi, F. Gaspari, R. Benini, and G. Remuzzi, “Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial,” The Lancet, vol. 352, no. 9136, pp. 1252–1256, 1998. View at Publisher · View at Google Scholar · View at Scopus
22. M. Ishizaki, Y. Masuda, and Y. Fukuda, “Experimental mesangioproliferative glomerulonephritis in rats induced by intravenous administration of anti-thymocyte serum,” Acta Pathologica Japonica, vol. 36, no. 8, pp. 1191–1203, 1986. View at Scopus
23. N. Sakai, K. Iseki, S. Suzuki et al., “Uninephrectomy induces progressive glomerulosclerosis and apoptosis in anti-Thy1 glomerulonephritis,” Pathology International, vol. 55, no. 1, pp. 19–26, 2005. View at Publisher · View at Google Scholar · View at Scopus
24. H. Kawachi, T. Iwanaga, S. Toyabe, T. Oite, and F. Shimizu, “Mesangial sclerotic change with persistent proteinuria in rats after two consecutive injections of monoclonal antibody 1-22-3,” Clinical and Experimental Immunology, vol. 90, no. 1, pp. 129–134, 1992. View at Scopus
25. T. Nakamura, J. E. Obata, H. Kimura et al., “Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis,” Kidney International, vol. 55, no. 3, pp. 877–889, 1999. View at Publisher · View at Google Scholar · View at Scopus
26. S. Kondo, M. Shimizu, M. Urushihara et al., “Addition of the antioxidant probucol to angiotensin II type I receptor antagonist arrests progressive mesangioproliferative glomerulonephritis in the rat,” Journal of the American Society of Nephrology, vol. 17, no. 3, pp. 783–794, 2006. View at Publisher · View at Google Scholar · View at Scopus
27. S. A. Gaertner, U. Janssen, T. Ostendorf, K. M. Koch, J. Floege, and W. Gwinner, “Glomerular oxidative and antioxidative systems in experimental mesangioproliferative glomerulonephritis,” Journal of the American Society of Nephrology, vol. 13, no. 12, pp. 2930–2937, 2002. View at Publisher · View at Google Scholar · View at Scopus
28. M. N. Budisavljevic, L. Hodge, K. Barber et al., “Oxidative stress in the pathogenesis of experimental mesangial proliferative glomerulonephritis,” American Journal of Physiology, vol. 285, no. 6, pp. F1138–F1148, 2003. View at Scopus
29. Y. Gorin, J. M. Ricono, B. Wagner et al., “Angiotensin II-induced ERK1/ERK2 activation and protein synthesis are redox-dependent in glomerular mesangial cells,” Biochemical Journal, vol. 381, part 1, pp. 231–239, 2004. View at Publisher · View at Google Scholar · View at Scopus
30. M. Shibanuma, J. I. Mashimo, T. Kuroki, and K. Nose, “Characterization of the TGFβ1-inducible hic-5 gene that encodes a putative novel zinc finger protein and its possible involvement in cellular senescence,” Journal of Biological Chemistry, vol. 269, no. 43, pp. 26767–26774, 1994. View at Scopus
31. M. Matsuya, H. Sasaki, H. Aoto et al., “Cell adhesion kinase β forms a complex with a new member, Hic-5, of proteins localized at focal adhesions,” Journal of Biological Chemistry, vol. 273, no. 2, pp. 1003–1014, 1998. View at Publisher · View at Google Scholar · View at Scopus
32. D. A. Tumbarello and C. E. Turner, “Hic-5 contributes to epithelial-mesenchymal transformation through a RhoA/ROCK-dependent pathway,” Journal of Cellular Physiology, vol. 211, no. 3, pp. 736–747, 2007. View at Publisher · View at Google Scholar · View at Scopus
33. G. Dabiri, D. A. Tumbarello, C. E. Turner, and L. Van de Water, “Hic-5 promotes the hypertrophic scar myofibroblast phenotype by regulating the TGF-β1 autocrine loop,” Journal of Investigative Dermatology, vol. 128, no. 10, pp. 2518–2525, 2008. View at Publisher · View at Google Scholar · View at Scopus
34. K. Suga, S. Kondo, S. Matsuura, et al., “Glomerular expression of hydrogen peroxide inducible clone-5 in human and rat progressive mesagnial proliferative glomerulonephritis,” Nephron Experimental Nephrology, vol. 120, no. 2, pp. e59–e68, 2012.
35. S. Nishimoto and E. Nishida, “MAPK signalling: ERK5 versus ERK1/2,” EMBO Reports, vol. 7, no. 8, pp. 782–786, 2006. View at Publisher · View at Google Scholar · View at Scopus
36. D. Bokemeyer, D. Panek, H. J. Kramer et al., “In vivo identification of the mitogen-activated protein kinase cascade as a central pathogenic pathway in experimental mesangioproliferative glomerulonephritis,” Journal of the American Society of Nephrology, vol. 13, no. 6, pp. 1473–1480, 2002. View at Publisher · View at Google Scholar · View at Scopus
37. T. Masaki, C. Stambe, P. A. Hill, J. Dowling, R. C. Atkins, and D. J. Nikolic-Paterson, “Activation of the extracellular-signal regulated protein kinase pathway in human glomerulopathies,” Journal of the American Society of Nephrology, vol. 15, no. 7, pp. 1835–1843, 2004. View at Publisher · View at Google Scholar · View at Scopus
38. Y. Suzaki, M. Yoshizumi, S. Kagami et al., “BMK1 is activated in glomeruli of diabetic rats and in mesangial cells by high glucose conditions,” Kidney International, vol. 65, no. 5, pp. 1749–1760, 2004. View at Publisher · View at Google Scholar · View at Scopus
39. M. Urushihara, M. Takamatsu, M. Shimizu, et al., “ERK5 activation enhances mesangial cell viability and collagen matrix accumulation in rat progressive glomerulonephritis,” American Journal of Physiology Renal Physiology, vol. 298, no. 1, pp. F167–F176, 2009.
40. H. Okada, T. Inoue, T. Kikuta et al., “A possible anti-inflammatory role of angiotensin II type 2 receptor in immune-mediated glomerulonephritis during type 1 receptor blockade,” American Journal of Pathology, vol. 169, no. 5, pp. 1577–1589, 2006. View at Publisher · View at Google Scholar · View at Scopus
41. N. Ohashi, M. Urushihara, R. Satou, and H. Kobori, “Glomerular angiotensinogen is induced in mesangial cells in diabetic rats via reactive oxygen speciesERK/JNK pathways,” Hypertension Research, vol. 33, no. 11, pp. 1174–1181, 2010. View at Publisher · View at Google Scholar · View at Scopus
42. A. P. Lakshmanan, R. A. Thandavarayan, K. Watanabe, et al., “Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice,” Molecular and cellular endocrinology, vol. 348, no. 1, pp. 104–111, 2012.
43. H. Ha and Hi Bahl Lee, “Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose,” Kidney International, Supplement, vol. 58, no. 77, pp. S19–S25, 2000. View at Scopus
44. D. R. Tomlinson, “Mitogen-activated protein kinases as glucose transducers for diabetic complications,” Diabetologia, vol. 42, no. 11, pp. 1271–1281, 1999. View at Publisher · View at Google Scholar · View at Scopus
45. E. Tsiani, P. Lekas, I. G. Fantus, et al., “High glucose-enhanced activation of mesangial cell p38 MAPK by ET-1, ANG II, and platelet-derived growth factor,” American Journal of Physiology, vol. 282, no. 1, pp. E161–E169, 2002. View at Scopus
46. B. G. Hudson, K. Tryggvason, M. Sundaramoorthy, and E. G. Neilson, “Alport's syndrome, Goodpasture's syndrome, and type IV collagen,” The New England Journal of Medicine, vol. 348, no. 25, pp. 2543–2556, 2003. View at Publisher · View at Google Scholar · View at Scopus
47. M. Shimizu, S. Kondo, M. Urushihara et al., “Role of integrin-linked kinase in epithelial-mesenchymal transition in crescent formation of experimental glomerulonephritis,” Nephrology Dialysis Transplantation, vol. 21, no. 9, pp. 2380–2390, 2006. View at Publisher · View at Google Scholar · View at Scopus
48. T. Wada, H. Yokoyama, K. Furuichi et al., “Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF/MCP-1),” The FASEB Journal, vol. 10, no. 12, pp. 1418–1425, 1996. View at Scopus
49. Y. Kinoshita, S. Kondo, M. Urushihara, et al., “Angiotensin II type I receptor blockade suppresses glomerular renin-angiotensin system activation, oxidative stress, and progressive glomerular injury in rat anti-glomerular basement membrane glomerulonephritis,” Translational Research, vol. 158, no. 4, pp. 235–248, 2011.
50. T. Wada, K. Furuichi, N. Sakai et al., “A new anti-inflammatory compound, FR167653, ameliorates crescentic glomerulonephritis in Wistar-Kyoto rats,” Journal of the American Society of Nephrology, vol. 11, no. 8, pp. 1534–1541, 2000. View at Scopus
51. K. Matsushima, C. G. Larsen, G. C. DuBois, and J. J. Oppenheim, “Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line,” Journal of Experimental Medicine, vol. 169, no. 4, pp. 1485–1490, 1989. View at Scopus
52. Y. Ozawa, H. Kobori, Y. Suzaki, and L. G. Navar, “Sustained renal interstitial macrophage infiltration following chronic angiotensin II infusions,” The American Journal of Physiology, vol. 292, no. 1, pp. F330–F339, 2007. View at Publisher · View at Google Scholar · View at Scopus
53. S. Segerer, Y. Cui, K. L. Hudkins et al., “Expression of the chemokine monocyte chemoattractant protein-1 and its receptor chemokine receptor 2 in human crescentic glomerulonephritis,” Journal of the American Society of Nephrology, vol. 11, no. 12, pp. 2231–2242, 2000. View at Scopus
54. M. Urushihara, N. Ohashi, K. Miyata, R. Satou, O. W. Acres, and H. Kobori, “Addition of angiotensin II Type 1 receptor blocker to CCR2 antagonist markedly attenuates crescentic glomerulonephritis,” Hypertension, vol. 57, no. 3, pp. 586–593, 2011. View at Publisher · View at Google Scholar · View at Scopus
55. T. Wada, K. Matsushima, and K. I. Kobayashi, “Monocyte chemoattractant protein-1: does it play a role in diabetic nephropathy?” Nephrology Dialysis Transplantation, vol. 18, no. 3, pp. 457–459, 2003. View at Publisher · View at Google Scholar · View at Scopus
56. S. Kato, V. A. Luyckx, M. Ots et al., “Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats,” Kidney International, vol. 56, no. 3, pp. 1037–1048, 1999. View at Publisher · View at Google Scholar · View at Scopus
57. C. Zoja, D. Corna, D. Rottoli et al., “Effect of combining ACE inhibitor and statin in severe experimental nephropathy,” Kidney International, vol. 61, no. 5, pp. 1635–1645, 2002. View at Publisher · View at Google Scholar · View at Scopus
58. Y. M. Chen, M. I. Hu-Tsai, S. L. Lin, T. J. Tsai, and B. S. Hsieh, “Expression of CX3CL1/fractalkine by mesangial cells in vitro and in acute anti-Thy1 glomerulonephritis in rats,” Nephrology Dialysis Transplantation, vol. 18, no. 12, pp. 2505–2514, 2003. View at Publisher · View at Google Scholar · View at Scopus